​

Immuneering (IMRX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

IMRX Stock Forecast

Immuneering (IMRX) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $17.50, with a high of $41.00 and a low of $3.00. This represents a 1277.95% increase from the last price of $1.27.

- $9 $18 $27 $36 $45 High: $41 Avg: $17.5 Low: $3 Last Closed Price: $1.27

IMRX Stock Rating

Immuneering stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (66.67%), 3 Hold (33.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 3 6 0 Strong Sell Sell Hold Buy Strong Buy

IMRX Price Target Upside V Benchmarks

TypeNameUpside
StockImmuneering1277.95%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.27$1.27$1.27
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25221--5
Mar, 252311-7
Feb, 252311-7
Jan, 252311-7
Dec, 242321-8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 02, 2024Graig SuvannavejhMizuho Securities$8.00$2.75190.91%529.92%
Mar 15, 2024Michael YeeJefferies$3.00$1.9157.07%136.22%
Sep 30, 2022Swapnil MalekarPiper Sandler$41.00$15.50164.52%3128.35%
Jul 09, 2022Geulah LivshitsLoop Capital Markets$18.00$7.28147.25%1317.32%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 13, 2024Morgan StanleyUnderweightdowngrade
Apr 19, 2023Mizuho SecuritiesBuyupgrade
Jul 25, 2022Piper SandlerOverweightOverweighthold
Jul 09, 2022Chardan CapitalBuyinitialise

Financial Forecast

EPS Forecast

$-3K $-2K $-2K $-1K $-500 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.27$-1.87$-1.88$-2.04K----
Avg Forecast$-3.30$-1.93$-1.82$-1.82$-1.57$-1.74$-1.50$-0.86
High Forecast$-3.30$-1.93$-1.72$-1.62$-0.95$-0.83$-0.74$-0.86
Low Forecast$-3.30$-1.93$-1.87$-2.04$-2.33$-2.49$-2.54$-0.86
Surprise %-61.52%-3.11%3.30%111757.14%----

Revenue Forecast

$0 $15M $30M $45M $60M $75M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.08M$316.95K------
Avg Forecast$2.44M$447.43K$455.00-$1.09M$21.27M$33.40M$70.43M
High Forecast$2.44M$447.43K$455.00-$1.09M$21.27M$33.40M$70.43M
Low Forecast$2.44M$447.43K$455.00-$1.09M$21.27M$33.40M$70.43M
Surprise %-14.91%-29.16%------

Net Income Forecast

$-65B $-52B $-39B $-26B $-13B $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-33.54M$-49.28M$-53.47M$-61.04B----
Avg Forecast$-93.72M$-54.88M$-50.98M$-52.00M$-46.52M$-47.15M$-46.66M$-24.44M
High Forecast$-93.72M$-54.88M$-48.88M$-46.16M$-26.92M$-23.50M$-21.06M$-24.44M
Low Forecast$-93.72M$-54.88M$-53.09M$-57.84M$-66.12M$-70.79M$-72.26M$-24.44M
Surprise %-64.22%-10.21%4.88%117286.69%----

IMRX Forecast FAQ

Is Immuneering stock a buy?

Immuneering stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Immuneering is a favorable investment for most analysts.

What is Immuneering's price target?

Immuneering's price target, set by 9 Wall Street analysts, averages $17.5 over the next 12 months. The price target range spans from $3 at the low end to $41 at the high end, suggesting a potential 1277.95% change from the previous closing price of $1.27.

How does Immuneering stock forecast compare to its benchmarks?

Immuneering's stock forecast shows a 1277.95% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Immuneering over the past three months?

  • April 2025: 40.00% Strong Buy, 40.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 28.57% Strong Buy, 42.86% Buy, 14.29% Hold, 14.29% Sell, 0% Strong Sell.
  • February 2025: 28.57% Strong Buy, 42.86% Buy, 14.29% Hold, 14.29% Sell, 0% Strong Sell.

What is Immuneering’s EPS forecast?

Immuneering's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.57, marking a -99.92% decrease from the reported $-2.036K in 2024. Estimates for the following years are $-1.74 in 2026, $-1.5 in 2027, and $-0.86 in 2028.

What is Immuneering’s revenue forecast?

Immuneering's average annual revenue forecast for its fiscal year ending in December 2025 is $1.09M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $21.27M, followed by $33.4M for 2027, and $70.43M for 2028.

What is Immuneering’s net income forecast?

Immuneering's net income forecast for the fiscal year ending in December 2025 stands at $-46.52M, representing a -99.92% decrease from the reported $-61.037B in 2024. Projections indicate $-47.148M in 2026, $-46.661M in 2027, and $-24.438M in 2028.